CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.60 and traded as high as $6.59. CASI Pharmaceuticals shares last traded at $6.14, with a volume of 16,775 shares traded.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of CASI Pharmaceuticals in a research report on Saturday, August 3rd. They issued a “hold” rating for the company.
Check Out Our Latest Stock Analysis on CASI
CASI Pharmaceuticals Trading Down 5.1 %
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last issued its earnings results on Friday, August 16th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. The firm had revenue of $3.98 million during the quarter, compared to analyst estimates of $4.43 million. CASI Pharmaceuticals had a negative net margin of 118.81% and a negative return on equity of 126.20%. Equities research analysts expect that CASI Pharmaceuticals, Inc. will post -2.56 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in CASI Pharmaceuticals stock. Howland Capital Management LLC purchased a new stake in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned approximately 0.30% of CASI Pharmaceuticals as of its most recent SEC filing. 22.23% of the stock is currently owned by hedge funds and other institutional investors.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Recommended Stories
- Five stocks we like better than CASI Pharmaceuticals
- How to Buy Cheap Stocks Step by Step
- The Average 401k Balance by Age Explained
- What is the Nikkei 225 index?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 5 discounted opportunities for dividend growth investors
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.